Deerfield Management’s AstraZeneca AZN Stock Holding History

Deerfield Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-12,500	Closed	-$929K	–	134
2014 Q2	$929K	Buy	+12,500	New	+$904K	0.04%	111
2013 Q4	–	Sell	-928,000	Closed	-$48.2M	–	111
2013 Q3	$48.2M	Hold	928,000	–	–	2.24%	8
2013 Q2	$43.9M	Buy	+928,000	New	+$47.3M	2.07%	12

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Deerfield Management's AZN Position: Q3 2014 in Review

Deerfield Management sold out of AstraZeneca (AZN) in Q3 2014, closing a stake of 12,500 shares — an estimated $929K sold.

Deerfield Management first reported a position in AZN in Q2 2013 and held it in 3 quarters. The position peaked at $48.2M in Q3 2013. 402 funds tracked by Wall St. Rank hold AZN as of Q3 2014.

Deerfield Management reported no remaining AstraZeneca position as of Q3 2014 after selling out during the quarter.
Deerfield Management sold 12,500 AstraZeneca shares in Q3 2014, an estimated $929K.
Deerfield Management first reported a position in AstraZeneca in Q2 2013 and held it in 3 quarters.
Deerfield Management's AstraZeneca position peaked at $48.2M in Q3 2013.
402 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2014.

Based on Deerfield Management's 13F filing for Q3 2014, filed 14 Nov 2014.